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Abstract
Introduction: Idiopathic Autoimmune Hemolytic Anemia is a potentially fatal condition which requires
prompt and potent treatment. Diagnosis of idiopathic autoimmune hemolytic anemia requires both
serologic evidence of autoantibody presence and hemolysis. Although most of the times it is considered
idiopathic, several underlying causes have been identified, like autoimmune and connective tissue diseases,
viral infections, drugs or hyper function of the immune system. To our knowledge, this is the first case in
the international literature describing lecithin-induced autoimmune hemolytic anemia.
Case Presentation: This case report is to highlight a rare but dangerous adverse reaction to overdose
of lecithin. A 38 year old white female from Greece, presented to our emergency room with progressive
fatigue over a period of ten days and icteric discoloration of her skin and conjunctiva. The patient had been
taking lecithin supplements (1200 mg, 3 capsules a day) over a period of ten days for weight loss. She
reports that the last 3 days, prior to the examination, she took 5 capsules/day, so that the supplement
would take effect more rapidly. Her past medical, social and family history showed no disturbance.
Relatives of the patient were requested to submit any blood-tests taken over a period of 20 days prior to
the onset of symptoms caused by Lecithin. All tests proved that all functions were within normal scale.
Her physical examination revealed pallor and jaundice without palpable hepatosplenomegaly. Blood
biochemistry tests showed total bilirubin 7.5 mg/dl, with indirect bilirubin 6.4 mg/dl and complete blood
count showed hemoglobin 7.6 g/dl with blood levels 21.4%.
Conclusion:  In every case of idiopathic autoimmune hemolytic anemia the administration of
pharmaceutical substances should always be examined, except for the standard reasons that cause it. In
this case the cause of hemolysis was attributed to the excessive intake of lecithin capsules for the loss of
body weight. It is important that clinicians and immunologists are aware of this adverse effect.
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Introduction
Idiopathic Autoimmune Hemolytic Anemia is a poten-
tially fatal condition which requires prompt and potent
treatment. Diagnosis of idiopathic autoimmune hemo-
lytic anemia (IAIHA) requires both serologic evidence of
autoantibody existence and hemolysis. Sensitized red
blood cells (RBCs) are destroyed by intravascular and/or
extravascular hemolysis. Although most of the times it is
considered idiopathic (the cause of autoimmunization
remains obscure in 50% of the patients) [1], several
underlying causes have been identified, like autoimmune
and connective tissue diseases, viral infections, drugs or
malignancies of the immune system [2]. In the absence of
a clinically apparent underlying disorder, testing for the
presence of antinuclear antibodies, a serum protein elec-
trophoresis (SPE) and a Computer Tomography (CT)-
scan must be systematic. Conversely, if no abnormalities
are revealed, the relevance of a systematic medullar biopsy
(MB) at AIHA onset seems very low [3]. Phospholipids,
which include the compound phosphatidyl choline, the
chemical name for lecithin are lipids containing a phos-
phoric acid residue. The main phospholipids in lecithin
from soya and sunflower are phosphatidyl choline, phos-
phatidyl inositol, phosphatidyl ethanolamine, and phos-
phatidic acid. Although lecithin was first observed and
isolated from egg yolk in 1846, it was only 20 years later
that the choline component in lecithin was identified [2].
The role of polyunsaturated fatty acids in decreasing the
cholesterol levels in the blood is well founded in litera-
ture. In addition, dietary phospholipids from various ori-
gins, particularly polyunsaturated fatty acid
phospholipids, such as those of soy bean lecithin have a
cholesterol-lowering effect in humans [4]. There are stud-
ies which exhibit that soy-derived lecithin has significant
effects on lowering cholesterol and triglyceride, while
increasing high density lipoproteins (HDL) levels in the
blood. [5,6]. This case study is to highlight a rare but haz-
ardous adverse reaction to lecithin or to the other sub-
stances that the capsules contain. Consent was obtained
from the patient for publication of the hereby study. The
legal authorities have been notified of the adverse effect of
over consumption of lecithin.
Case presentation
A 38 year old white female from Greece, presented to our
emergency room with progressive fatigue over a period of
ten days and icteric discoloration of her skin and conjunc-
tiva. The patient had been taking lecithin supplements
(1200 mg, 3 capsules a day) over a period of ten days for
weight loss. Her medical, social and family history
revealed no possible cause for such a condition. Relatives
of the patient were requested to submit any blood-tests
taken over a period of 20 days prior to the onset of symp-
toms caused by Lecithin. All tests proved that all functions
were within normal scale: Haemoglobin 12.8 gr/dl, blood
levels 39.3%, Mean cell volume (MCV) 84.2 fl, mean cell
haemoglobin (MCH) 26.7 pg, mean cell haemoglobin
concentration (MCHC) 32.5 gr/dl, White Blood Cell
(WBC) 6400*1000/μl, Platelet counts (PLT)
210000*1000/μl, Urea 19 mg%, Creatinin 0.51 mg%,
Lactate Dehydrogenase (LDH) 140 IU/L, Total bilirubin
0.78 mg%, Indirect bilirubin 0.19 mr%. Chemical and
microscopic urine examination showed ph 5.5, s.w.1020,
leukocytes 2–3 cells/h.p.f., erythrocytes 0–1 cells/h.p.f.
and chemical and microscopic feces examination showed
leukocytes 2–3 cells/h.p.f., erythrocytes 0–1 cells/h.p.f.,
without vermins. She denied the consumption of any
medications, herbals or dietary supplements other than
lecithin capsules during the past four weeks. She was not
experiencing any shortness of breath or dyspnea on exer-
tion. After her hospital intake physical examination
revealed pallor and jaundice without palpable hepat-
osplenomegaly. No skin lesions or lymphadenopathy
were observed following routine cardiac, pulmonary and
abdominal examination. Blood biochemistry tests
showed total bilirubin 7.5 mg/dl, with indirect bilirubin
6.4 mg/dl and increased LDH 405 IU/L. Liver function
tests and the rest of the comprehensive metabolic panel
(CMP) was within normal limits. Complete Blood Count
showed haemoglobin 7.6 g/dl with blood levels 21.4%.
MCV 99 fl, MCH 29.6 pg and MCHC 29.5 g/dl. White
Blood Cell and Platelet counts were normal. Reticulocyte
count was 15%. The peripheral blood smear showed
spherocytes. (Fig. 1). Direct Antiglobulin Test (DAT) was
positive for anti-IgG, but tests for anti-nuclear antibodies
(ANA) and Rheumatoid Factor were negative, Thyroid
function tests(T3 1.72 ng/ml, T4 9.45 μg/dl, TSH 2.07
μIU/ml) and Serum Protein Electrophoresis (Albumines
61%, a1 2.8%, a2 9.5%, β 10.4%, γ 13.2%) were unre-
markable. C3 complement (0.99 gr/l), C4 (0,05 gr/l) and
IgG (16,50 gr/l) were within normal rates. CT scan of the
chest, abdomen and pelvis were unremarkable. Finally,
bone marrow biopsy that was performed can be seen in
The peripheral blood smear showing spherocytes Figure 1
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(Fig 2). The patient was prescribed for prednisolone 60
mg per day. Her clinical picture during the 10-day hospi-
talization was uneventful. The patient was re-examined
after four weeks, and her clinical and biochemical profile
returned to normal without residual deficits or complica-
tions. She denied any consumption of lecithin, over this
period; therefore our medical team did not conduct any
further research.
Discussion
Idiopathic autoimmune hemolytic anemia results from
auto antibodies' production. Depending on the special
characteristics of those antibodies, there are different
types of autoimmune hemolytic anemia, a) Cold aggluti-
nin disease, b) Warm agglutinin disease c) Donath-Land-
steiner disease and d) drug-induced where auto
antibodies are Ig-G type.
There are different underlying mechanisms of drug-
induced autoimmune hemolytic anemia [7].
1. Drug-absorption. An epitope of the drug (lecithin)
attach to the proteins of the erythrocyte membrane and
finally leads to IgG antibodies formations.
2. Immune Complex Formation. When the substance
combines with the plasma protein, it creates a complex
which triggers the formation of antibodies against it. The
new immune complex attaches to the RBC membrane and
activates the complement which consequently leads to
intravascular haemolysis.
3. The drug affects immune cells, so that it causes immune
answer: DAT positive.
4. Probably the drug changes RBC membrane and that
makes it vulnerable to the complement but nonspecifi-
cally, so that RBC's are destroyed extravascularly and that
results in a negative DAT. [7].
In everyday clinical practice it is sometimes difficult to
define the exact mechanism with which a pharmaceutical
substance causes hemolysis, because more than one of the
mechanisms that are mentioned before is involved. Fun-
damental step to the differential diagnosis of autoim-
mune hemolytic anemia is the exclusion of the remaining
pathological conditions that cause it such as lymphohy-
perplastic disease, neoplasia, connective tissue disorders,
thyroid gland disease, chronic hepatitis, and infections
such as Ebstein-Barr Virus (EBV), Cytomegalovirus
(CMV), Human Immunodeficiency Virus (HIV) and Myc-
oplasma.
In the present case all the above were excluded based on
the history, the objective examination, and the laboratory
findings. Consequently, the cause of autoimmune
haemolytic anemia due to the administration of overdose
of lecithin (or to the other components of the capsule) is
very probable. The causing mechanism which is based on
the positive DAT as antibody Ig-G and the action of leci-
thin as a drug absorption mechanism, or antibodies
induction due to modification of RBC membrane by leci-
thin.
Conclusion
To our knowledge this is the first case in the international
literature describing lecithin-induced idiopathic autoim-
mune hemolytic anemia. Our treatment was in compli-
ance with the recommended standard treatment of
hemolytic anemia, with the discontinuation of the phar-
maceutical agent, and namely the discontinuation of leci-
thin capsules, and the beginning of treatment with
corticoids and it was efficient. It is important to the clini-
cians to be aware of this adverse effect and conduct more
research. In every case of autoimmune hemolytic anaemia
the administration of pharmaceutical substances should
always be examined detached from the standard reasons
that cause it. In this case the cause of hemolysis was attrib-
uted to the intake of an overdose of lecithin capsules for
the loss of body weight.
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